Literature DB >> 28450819

Reversal of Immunogenicity in Inflammatory Bowel Disease.

Shomron Ben-Horin1.   

Abstract

Year:  2017        PMID： 28450819      PMCID： PMC5402684     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  7 in total

1.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Authors:  Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

2.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Authors:  Niels Vande Casteele; Marc Ferrante; Gert Van Assche; Vera Ballet; Griet Compernolle; Kristel Van Steen; Steven Simoens; Paul Rutgeerts; Ann Gils; Séverine Vermeire
Journal:  Gastroenterology       Date:  2015-02-24       Impact factor: 22.682

Review 3.  Tailoring anti-TNF therapy in IBD: drug levels and disease activity.

Authors:  Shomron Ben-Horin; Yehuda Chowers
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-01-07       Impact factor: 46.802

Review 4.  Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.

Authors:  A C Moss; V Brinks; J F Carpenter
Journal:  Aliment Pharmacol Ther       Date:  2013-10-03       Impact factor: 8.171

5.  Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.

Authors:  B Ungar; U Kopylov; T Engel; M Yavzori; E Fudim; O Picard; A Lang; N Williet; S Paul; Y Chowers; A Bar-Gil Shitrit; R Eliakim; S Ben-Horin; X Roblin
Journal:  Aliment Pharmacol Ther       Date:  2016-11-16       Impact factor: 8.171

6.  Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

Authors:  Shomron Ben-Horin; Matti Waterman; Uri Kopylov; Miri Yavzori; Orit Picard; Ella Fudim; Halim Awadie; Batia Weiss; Yehuda Chowers
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-24       Impact factor: 11.382

Review 7.  Optimizing the use of biological therapy in patients with inflammatory bowel disease.

Authors:  Alan C Moss
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-01-06
  7 in total
  1 in total

Review 1.  The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.

Authors:  Grainne Holleran; Loris Lopetuso; Valentina Petito; Cristina Graziani; Gianluca Ianiro; Deirdre McNamara; Antonio Gasbarrini; Franco Scaldaferri
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.